Allergy drug sits at the center of this dementia and brain health question.
The allergy drug that a growing number of pediatricians now refuse to prescribe for young kids is diphenhydramine, sold under the brand name Benadryl. Once considered a medicine cabinet staple, this first-generation antihistamine has come under intense scrutiny from leading allergy experts, hospital systems, and even the FDA itself. In February 2025, researchers from Johns Hopkins University and the University of California, San Diego published a peer-reviewed paper titled “Diphenhydramine: It Is Time to Say a Final Goodbye,” arguing the drug should be pulled from both over-the-counter and prescription markets entirely. Their conclusion was blunt: diphenhydramine “has reached the end of its life cycle” and represents a “relatively greater public health hazard” compared to modern alternatives.
This shift matters beyond pediatrics. Diphenhydramine’s well-documented anticholinergic effects have long concerned brain health researchers studying cognitive decline and dementia risk in older adults, and the same pharmacological properties that make it dangerous for developing brains raise parallel concerns across the lifespan. The experts behind the 2025 review went so far as to say the drug “would probably not get approved today by the FDA, just due to the sedating effects.” For parents who have reflexively reached for the pink bottle at the first sign of hives or seasonal sniffles, this represents a genuine reckoning. This article covers why pediatricians are walking away from diphenhydramine, what hospital-level data reveals about the harms of first-generation antihistamines in children, the FDA petition seeking to remove the drug from store shelves, what safer alternatives exist, and why another common allergy medication — montelukast — has drawn its own serious safety warnings.
Table of Contents
- Why Are Pediatricians Refusing to Prescribe This Common Allergy Drug for Young Kids?
- What Hospital Data Reveals About First-Generation Antihistamines and Pediatric Harm
- The FDA Petition to Remove Diphenhydramine From Store Shelves
- What Pediatricians Recommend Instead of Diphenhydramine
- The Brain Health Angle — Anticholinergic Drugs and Cognitive Risk
- Montelukast — Another Allergy Drug With Serious Safety Warnings for Children
- Where Pediatric Allergy Treatment Goes From Here
- Conclusion
- Frequently Asked Questions
Why Are Pediatricians Refusing to Prescribe This Common Allergy Drug for Young Kids?
The reasons pediatricians are abandoning diphenhydramine go beyond the usual “newer is better” logic. In children, the drug frequently produces paradoxical effects — instead of the drowsiness adults experience, kids can become hyperactive, agitated, and unable to sleep. A parent who gives their child Benadryl expecting it to calm an allergic reaction may instead find themselves dealing with a wired, irritable kid at two in the morning. this unpredictability alone has made many pediatricians uncomfortable recommending it, but the risks extend much further. Accidental overdose is a genuine and documented danger. The 2025 Johns Hopkins review cites cases of accidental pediatric ingestion of diphenhydramine formulations leading to extreme sedation, coma, seizures, and death.
The drug’s availability in liquid pediatric formulations — often grape- or cherry-flavored — makes it particularly vulnerable to accidental overconsumption by young children. And then there is the social media dimension: the so-called “Benadryl Challenge” on TikTok was linked to multiple child hospitalizations and fatalities, with teenagers deliberately consuming dangerous quantities of the drug for online attention. Experts also confirm that diphenhydramine is not effective for cold symptoms in children and should never be used as a sleep aid for kids, despite widespread parental use for both purposes. The FDA itself states that children under age 2 should not be given any decongestant or antihistamine due to the risk of convulsions, rapid heart rate, and death. The American Academy of Pediatrics does not recommend oral decongestants for children at all. When a drug fails to work for the purposes people most commonly use it for, and carries serious risks in the process, the clinical case for prescribing it collapses.
What Hospital Data Reveals About First-Generation Antihistamines and Pediatric Harm
The argument against diphenhydramine is not just theoretical. A study led by Dr. Katelyn Wong at Yale School of Medicine, conducted across approximately 7,000 pediatric patients ranging from 6 months to 21 years old between 2022 and 2024 and published in 2026, demonstrated that hospitals could successfully slash the use of first-generation antihistamines by switching clinical pathways to cetirizine, known by the brand name Zyrtec. The study’s findings were telling: first-generation antihistamines including diphenhydramine and hydroxyzine were associated with oversedation, coma, seizures, ADHD-like symptoms, and impaired learning in children. Perhaps the most striking finding from Wong’s research was that the overuse of older antihistamines in hospital settings was driven more by “habit and system design” than by clinical necessity.
In other words, doctors and nurses were not choosing diphenhydramine because the evidence supported it — they were choosing it because the order sets, protocols, and institutional inertia pointed them there. When hospitals deliberately restructured their clinical pathways to default to cetirizine, the transition happened smoothly and patient outcomes did not suffer. However, this does not mean cetirizine is without any drawbacks. Some children experience mild drowsiness with cetirizine, particularly at higher doses, and individual responses can vary. The important distinction is one of degree and safety margin: the gap between a therapeutic dose and a dangerous dose is far wider with second-generation antihistamines than with diphenhydramine. For any parent whose child is currently taking diphenhydramine under a doctor’s direction, the appropriate step is a conversation with that prescribing physician — not an abrupt, unilateral switch.
The FDA Petition to Remove Diphenhydramine From Store Shelves
In November 2025, experts from Johns Hopkins and the University of Florida took the extraordinary step of filing a citizen petition with the FDA arguing that diphenhydramine should be removed from over-the-counter availability entirely. The petition cited evidence that adverse reactions occur even at recommended dosages — not just in cases of misuse or overdose. Among the severe outcomes documented were seizures, abuse potential, and death. This is not a fringe effort; the researchers behind the petition are affiliated with two of the country’s most respected medical institutions. The petition represents a significant escalation.
Calling for a drug to be removed from OTC status is a serious regulatory request, and it reflects the petitioners’ judgment that voluntary label changes and public education campaigns have failed to adequately protect children. The FDA has not yet acted on the petition as of early 2026, and the regulatory process for such decisions is typically slow. But the filing itself has added momentum to a broader medical consensus that diphenhydramine’s era should end. For families, the practical implication is straightforward even before the FDA acts: if leading allergy experts at Johns Hopkins, Yale, UC San Diego, and the University of Florida all agree that this drug should not be available without a prescription — or at all — parents should take that consensus seriously. The fact that diphenhydramine remains on drugstore shelves does not mean it has been recently evaluated and deemed safe by the FDA. Its OTC status reflects regulatory decisions made decades ago, under a very different understanding of the drug’s risk profile.
What Pediatricians Recommend Instead of Diphenhydramine
The alternatives to diphenhydramine are well established, widely available, and in most cases cheaper than parents expect. Pediatricians now recommend three second-generation, non-sedating antihistamines: cetirizine (Zyrtec), loratadine (Claritin), and fexofenadine (Allegra). All three are available over the counter, come in child-friendly liquid formulations, and have safety profiles that have been studied extensively in pediatric populations. Each option has its own characteristics worth understanding. Cetirizine tends to be the most potent of the three and works relatively quickly, but it is also the most likely among second-generation options to cause mild drowsiness in some children. Loratadine is the least sedating but may take longer to reach full effect.
Fexofenadine sits somewhere in the middle and has the advantage of not crossing the blood-brain barrier as readily, which is relevant for families concerned about cognitive effects. None of these drugs carry the anticholinergic burden that makes diphenhydramine a concern for brain health across all age groups. The tradeoff parents sometimes perceive is speed. Diphenhydramine does act fast — typically within 15 to 30 minutes — and for acute allergic reactions, that speed felt reassuring. But cetirizine also acts relatively quickly, often within an hour, and its effects last significantly longer. For truly severe allergic reactions such as anaphylaxis, epinephrine — not any antihistamine — is the appropriate first-line treatment. No antihistamine, old or new, is a substitute for an EpiPen in an emergency.
The Brain Health Angle — Anticholinergic Drugs and Cognitive Risk
For readers of a brain health publication, the diphenhydramine story carries an additional layer of concern that extends well beyond pediatrics. Diphenhydramine is a potent anticholinergic drug, meaning it blocks acetylcholine, a neurotransmitter critical for memory, attention, and learning. In children, the Yale study documented associations with impaired learning and ADHD-like symptoms. In older adults, the cumulative use of anticholinergic medications — including diphenhydramine — has been linked in epidemiological research to increased dementia risk. This is a critical point for multigenerational families where a grandparent with cognitive concerns and a grandchild with allergies may both have diphenhydramine in the household.
The same pharmacological mechanism that impairs a child’s learning capacity is the mechanism that concerns dementia researchers studying long-term anticholinergic exposure in aging populations. Switching a child to cetirizine is not just a pediatric safety decision; it is a household-level risk reduction strategy. A limitation worth noting: the dementia-anticholinergic link, while supported by multiple large observational studies, remains an area of active research. Correlation is not causation, and not every person who takes Benadryl occasionally will develop cognitive problems. The concern is primarily about cumulative, long-term, or frequent exposure — which is exactly the pattern that emerges when a family relies on diphenhydramine as a go-to remedy for seasonal allergies, sleep difficulties, or cold symptoms across years.
Montelukast — Another Allergy Drug With Serious Safety Warnings for Children
Diphenhydramine is not the only common allergy medication that has drawn major safety scrutiny in recent years. In March 2020, the FDA added a black box warning — its strongest possible safety alert — to montelukast, sold under the brand name Singulair. The warning cited serious mental health side effects including suicidal thoughts, aggression, anxiety, depression, and sleep disturbances in children.
The FDA advised that montelukast should be reserved for allergic rhinitis only in patients who cannot tolerate or do not respond to other treatments. Interestingly, a large 2025 study published in PubMed found no association between montelukast use and neuropsychiatric events in routine clinical practice, even as spontaneous adverse event reports continue to accumulate. This disconnect between clinical trial data and real-world adverse event reporting is a recurring challenge in drug safety, and it means parents and physicians must weigh the available evidence carefully rather than relying on any single study. For children with both asthma and allergies, montelukast may still be appropriate — but it should not be a first-line allergy treatment when safer antihistamines are available.
Where Pediatric Allergy Treatment Goes From Here
The trajectory is clear. Between the Johns Hopkins review calling for diphenhydramine’s retirement, the Yale hospital study proving that clinical systems can successfully transition away from first-generation antihistamines, and the FDA citizen petition seeking to remove the drug from OTC status, the medical establishment is moving decisively toward a post-diphenhydramine era in pediatric care. The question is no longer whether diphenhydramine should be abandoned for children, but how quickly the regulatory and commercial systems will catch up to the clinical consensus.
For parents, the actionable takeaway does not require waiting for the FDA. Second-generation antihistamines are already available, affordable, and recommended by the AAP and leading pediatric allergists. The next time allergy season arrives or hives appear, the reach should be for cetirizine, loratadine, or fexofenadine — not the pink bottle that previous generations trusted but that the evidence no longer supports. And for anyone in the household concerned about long-term brain health, eliminating routine anticholinergic exposure is one of the more straightforward risk-reduction steps available.
Conclusion
The shift away from diphenhydramine in pediatric care is not a matter of medical fashion or overcaution. It reflects decades of accumulated evidence showing that this first-generation antihistamine causes paradoxical reactions in children, carries real overdose and death risk even in pediatric formulations, impairs learning and cognition through its anticholinergic mechanism, and offers no advantage over safer modern alternatives. When leading researchers from Johns Hopkins, Yale, UC San Diego, and the University of Florida all converge on the same conclusion — that this drug’s risks outweigh its benefits — parents and caregivers should listen. The practical steps are simple.
Replace diphenhydramine with cetirizine, loratadine, or fexofenadine for pediatric allergy management. Never use any antihistamine or decongestant in children under 2. Keep epinephrine, not antihistamines, as the first-line response for severe allergic reactions. And recognize that reducing anticholinergic drug exposure is a brain health strategy that benefits every member of the household, from the youngest to the oldest.
Frequently Asked Questions
Is it ever safe to give a child Benadryl?
While diphenhydramine remains legally available over the counter, leading allergy experts from Johns Hopkins and UC San Diego have concluded that its risks outweigh its benefits in all populations, including children. Safer alternatives like cetirizine, loratadine, and fexofenadine are widely available. The FDA states that no antihistamine or decongestant should be given to children under age 2.
Why do some emergency rooms still use diphenhydramine?
The Yale study led by Dr. Katelyn Wong found that overuse of first-generation antihistamines in hospitals was driven primarily by “habit and system design” rather than clinical evidence. Hospitals that restructured their protocols to default to cetirizine successfully reduced diphenhydramine use without compromising patient care.
Can diphenhydramine cause hyperactivity in kids instead of drowsiness?
Yes. Paradoxical effects are well documented in children. Instead of the sedation adults typically experience, diphenhydramine can cause hyperactivity, agitation, and insomnia in pediatric patients — the opposite of what parents expect when administering the drug.
Is Singulair (montelukast) safe for children with allergies?
The FDA added its strongest warning — a black box warning — to montelukast in March 2020 for serious mental health side effects including suicidal thoughts, aggression, and depression in children. The FDA advises it should only be used for allergies in children who cannot tolerate or do not respond to other treatments. A 2025 study found no association with neuropsychiatric events in routine clinical practice, but adverse event reports continue.
Does long-term Benadryl use affect brain health?
Diphenhydramine is a potent anticholinergic drug that blocks acetylcholine, a neurotransmitter essential for memory and learning. In children, it has been associated with impaired learning and ADHD-like symptoms. In older adults, cumulative anticholinergic exposure has been linked in epidemiological research to increased dementia risk, though causation has not been definitively established.
What should I use instead of Benadryl for my child’s allergies?
Pediatricians recommend second-generation antihistamines: cetirizine (Zyrtec), loratadine (Claritin), or fexofenadine (Allegra). These are non-sedating, have wider safety margins, and are available over the counter in child-friendly formulations. For severe allergic reactions, epinephrine — not any antihistamine — is the appropriate first-line treatment.
You Might Also Like
- Why Doctors Are Now Cautious About This Prostate Drug
- The Pediatric Drug Recall That’s Affecting Millions of Parents Right Now
- Why Some Kids Get Addicted to Nasal Spray — And How to Stop
For more, see National Institute on Aging.
